JP2014516530A - イヌインフルエンザ組み換えウイルス及びその製造方法、並びにその応用 - Google Patents
イヌインフルエンザ組み換えウイルス及びその製造方法、並びにその応用 Download PDFInfo
- Publication number
- JP2014516530A JP2014516530A JP2014511717A JP2014511717A JP2014516530A JP 2014516530 A JP2014516530 A JP 2014516530A JP 2014511717 A JP2014511717 A JP 2014511717A JP 2014511717 A JP2014511717 A JP 2014511717A JP 2014516530 A JP2014516530 A JP 2014516530A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- canine influenza
- gene
- seq
- recombinant virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 100
- 241000282465 Canis Species 0.000 title claims abstract description 74
- 206010022000 influenza Diseases 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 47
- 241000287828 Gallus gallus Species 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 229960003971 influenza vaccine Drugs 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000013612 plasmid Substances 0.000 claims description 22
- 239000012530 fluid Substances 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 15
- 210000003837 chick embryo Anatomy 0.000 claims description 14
- 101150039660 HA gene Proteins 0.000 claims description 12
- 101150080862 NA gene Proteins 0.000 claims description 12
- 210000001161 mammalian embryo Anatomy 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 238000012300 Sequence Analysis Methods 0.000 claims description 6
- 230000004520 agglutination Effects 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 230000004931 aggregating effect Effects 0.000 claims 1
- 230000035931 haemagglutination Effects 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 8
- 210000002257 embryonic structure Anatomy 0.000 abstract description 6
- 238000011081 inoculation Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 21
- 101710154606 Hemagglutinin Proteins 0.000 description 15
- 108010006232 Neuraminidase Proteins 0.000 description 15
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 15
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 15
- 101710176177 Protein A56 Proteins 0.000 description 15
- 239000000185 hemagglutinin Substances 0.000 description 15
- 235000013330 chicken meat Nutrition 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 102000005348 Neuraminidase Human genes 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 241000252870 H3N2 subtype Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 231100000645 Reed–Muench method Toxicity 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000252869 H3N8 subtype Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110139528.3 | 2011-05-26 | ||
| CN2011101395283A CN102220293B (zh) | 2011-05-26 | 2011-05-26 | 犬流感重组病毒及其制备方法和应用 |
| PCT/CN2012/074722 WO2012159522A1 (zh) | 2011-05-26 | 2012-04-26 | 犬流感重组病毒及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516530A true JP2014516530A (ja) | 2014-07-17 |
| JP2014516530A5 JP2014516530A5 (enExample) | 2015-04-23 |
Family
ID=44776999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511717A Pending JP2014516530A (ja) | 2011-05-26 | 2012-04-26 | イヌインフルエンザ組み換えウイルス及びその製造方法、並びにその応用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140286979A1 (enExample) |
| EP (1) | EP2716752A4 (enExample) |
| JP (1) | JP2014516530A (enExample) |
| KR (1) | KR20140031912A (enExample) |
| CN (1) | CN102220293B (enExample) |
| CA (1) | CA2837126A1 (enExample) |
| WO (1) | WO2012159522A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602697A (zh) * | 2017-08-29 | 2018-01-19 | 杭州医学院 | 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102220293B (zh) * | 2011-05-26 | 2012-12-19 | 中国农业科学院上海兽医研究所 | 犬流感重组病毒及其制备方法和应用 |
| CN103881983B (zh) * | 2014-03-07 | 2016-08-31 | 中国农业科学院哈尔滨兽医研究所 | 重组犬流感病毒毒株、其制备方法及由其制备得到的疫苗 |
| KR101633489B1 (ko) | 2015-02-25 | 2016-06-27 | 고패스 주식회사 | 통풍수단이 구비된 신발의 사출식 제조방법 |
| EP3313440A2 (en) | 2015-06-26 | 2018-05-02 | Merial, Inc. | Inactivated canine influenza vaccines and methods of making and uses thereof |
| CN105647877A (zh) * | 2016-02-02 | 2016-06-08 | 南京农业大学 | 一株低毒力重组猪脑心肌炎病毒及其应用 |
| CN113173976B (zh) * | 2021-06-03 | 2022-07-12 | 北京市农林科学院 | 一种犬流感病毒h3亚型ha蛋白、其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1624116A (zh) * | 2003-12-02 | 2005-06-08 | 中国农业科学院哈尔滨兽医研究所 | 人工重组的流感病毒及其应用 |
| JP2011501950A (ja) * | 2007-10-30 | 2011-01-20 | バイオノートインコーポレイテッド | 新規のイヌインフルエンザウイルス及びこのワクチン |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345716B1 (en) * | 1999-04-06 | 2015-01-14 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
| US7384642B2 (en) * | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
| BRPI0617735B1 (pt) * | 2005-10-19 | 2022-05-17 | University Of Florida Research Foundation Inc | Composições compreendendo vírus isolados, polinucleotídeos, ou polipeptídeos, construções de expressão, vacinas, kits para proteger um canino da infecção do vírus influenza, uso do vírus na preparação de composição farmacêutica bem como método in vitro para detecção de um vírus influenza que é capaz de infectar um animal canídeo |
| JP2010539093A (ja) * | 2007-09-10 | 2010-12-16 | インターベツト・インターナシヨナル・ベー・ベー | イヌ、ネコ及びウマにおけるインフルエンザ感染を予防するための組成物及び方法 |
| CN102220293B (zh) * | 2011-05-26 | 2012-12-19 | 中国农业科学院上海兽医研究所 | 犬流感重组病毒及其制备方法和应用 |
-
2011
- 2011-05-26 CN CN2011101395283A patent/CN102220293B/zh active Active
-
2012
- 2012-04-26 EP EP12790131.2A patent/EP2716752A4/en not_active Withdrawn
- 2012-04-26 CA CA2837126A patent/CA2837126A1/en not_active Abandoned
- 2012-04-26 KR KR1020137031403A patent/KR20140031912A/ko not_active Withdrawn
- 2012-04-26 WO PCT/CN2012/074722 patent/WO2012159522A1/zh not_active Ceased
- 2012-04-26 JP JP2014511717A patent/JP2014516530A/ja active Pending
- 2012-04-26 US US14/119,366 patent/US20140286979A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1624116A (zh) * | 2003-12-02 | 2005-06-08 | 中国农业科学院哈尔滨兽医研究所 | 人工重组的流感病毒及其应用 |
| JP2011501950A (ja) * | 2007-10-30 | 2011-01-20 | バイオノートインコーポレイテッド | 新規のイヌインフルエンザウイルス及びこのワクチン |
Non-Patent Citations (1)
| Title |
|---|
| JPN6016009551; ＰＬｏＳ Ｃｕｒｒ． Ｖｏｌ．２, 20100905, ＲＲＮ１１６５ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602697A (zh) * | 2017-08-29 | 2018-01-19 | 杭州医学院 | 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用 |
| CN107602697B (zh) * | 2017-08-29 | 2020-05-05 | 杭州医学院 | 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2716752A4 (en) | 2014-04-30 |
| KR20140031912A (ko) | 2014-03-13 |
| WO2012159522A1 (zh) | 2012-11-29 |
| CN102220293B (zh) | 2012-12-19 |
| EP2716752A1 (en) | 2014-04-09 |
| US20140286979A1 (en) | 2014-09-25 |
| CA2837126A1 (en) | 2012-11-29 |
| CN102220293A (zh) | 2011-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7691380B2 (ja) | Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス | |
| CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| CN115998856B (zh) | 一种新冠流感免疫原性组合物及其制备方法和应用 | |
| JP2014516530A (ja) | イヌインフルエンザ組み換えウイルス及びその製造方法、並びにその応用 | |
| US20140227310A1 (en) | Recombinant influenza virus highly expressing ha protein and preparation method and use thereof | |
| CN103266090B (zh) | Asia1型口蹄疫重组病毒及其制备方法和应用 | |
| CN103627718B (zh) | 表达ibv s1和n双抗原蛋白重组质粒及其构建方法和应用 | |
| CN108660118B (zh) | 一种导致鸭关节炎的新型鸭呼肠孤病毒及其应用 | |
| CN105671002B (zh) | H9n2亚型禽流感病毒细胞高产疫苗株构建及应用 | |
| KR20140010583A (ko) | 면역원성이 향상된 인플루엔자 바이러스의 ｈａ2 공통 에피톱의 제조 방법 | |
| CN102526718B (zh) | 一种重组h5n1禽流感病毒细胞苗及应用 | |
| CN104073470A (zh) | 一种h9n2亚型禽流感病毒的转瓶培养方法 | |
| CN101293099B (zh) | 一种抗多种亚型禽流感病毒的多肽疫苗及其制备方法 | |
| CN105985446B (zh) | 可优化病毒复制的培养基 | |
| CN102190701B (zh) | 一种流感病毒血凝素大规模分离纯化方法 | |
| CN102370976B (zh) | 猪流感病毒和猪口蹄疫病毒的混合病毒样颗粒、制备方法和应用 | |
| CN108602860B (zh) | 通过去脂作用灭活病毒 | |
| KR20130051799A (ko) | 고생산성, 고면역원성, 및 무병원성 인플루엔자 바이러스 제작용 재조합 발현 벡터 | |
| CN102839160A (zh) | 高效表达ha蛋白的重组流感病毒及其制备方法和应用 | |
| Duong et al. | Expression and purification capsid proteins Vp0, Vp1 and Vp3 of foot and mouth disease virus type O in Escherichia coli | |
| KR101414225B1 (ko) | 발육계란 고증식성 인플루엔자 바이러스 제작용 재조합 발현 벡터 | |
| CN116064424A (zh) | 表达传染性法氏囊炎病毒变异株vp2蛋白的新城疫病毒弱毒株及其制备方法和应用 | |
| CN116814562A (zh) | 基于目的基因S1的人5型复制缺陷型重组腺病毒、制备方法及用于预防SARS-CoV-2感染的疫苗 | |
| CN110760616A (zh) | 新城疫病毒和h9n2亚型禽流感病毒检测阳性标准品及其制备方法与应用 | |
| CN102864129A (zh) | 高效表达ha蛋白的重组流感病毒及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150303 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150303 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160315 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161018 |